FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, particularly to new drugs and preparations containing effective anticancer agent with anti-Hsp90 antibody.
EFFECT: invention improves clinical effectiveness in treating cancer and leukemia.
48 cl, 25 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF HEAT SHOCK PROTEINS FOR IMPROVEMENT OF THERAPEUTICAL EFFECT OF NON-VACCINAL MEDICINAL EFFECT | 2003 |
|
RU2376029C2 |
| USING HEAT SHOCK PROTEINS FOR IMPROVING THERAPEUTIC EFFECT OF NON-VACCINE THERAPEUTIC INTERVENTION | 2009 |
|
RU2573380C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
| COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
| COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| TREATMENT OF MYCOTIC INFECTION WITH ANTIMYCOTIC PREPARATIONS OUT OF POLYENIC GROUP OR THAT OF BETA-GLUCANSINTASE INHIBITORS IN COMBINATION WITH ANTI-hsp90-ANTIBODIES | 2001 |
|
RU2262952C2 |
